These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 26721266)

  • 1. Nanosuspension: Principles, Perspectives and Practices.
    Singh SK; Vaidya Y; Gulati M; Bhattacharya S; Garg V; Pandey NK
    Curr Drug Deliv; 2016; 13(8):1222-1246. PubMed ID: 26721266
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nanosuspensions in drug delivery: recent advances, patent scenarios, and commercialization aspects.
    Chavhan SS; Petkar KC; Sawant KK
    Crit Rev Ther Drug Carrier Syst; 2011; 28(5):447-88. PubMed ID: 22077201
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nanosuspensions: a promising drug delivery strategy.
    Patravale VB; Date AA; Kulkarni RM
    J Pharm Pharmacol; 2004 Jul; 56(7):827-40. PubMed ID: 15233860
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nanosuspensions as a versatile carrier based drug delivery system--an overview.
    Sudhakar B; NagaJyothi K; Murthy KV
    Curr Drug Deliv; 2014; 11(3):299-305. PubMed ID: 24655052
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Study of effect of variables on particle size of telmisartan nanosuspensions using box-Behnken design.
    Rao MR; Bajaj A
    Drug Res (Stuttg); 2014 Dec; 64(12):663-7. PubMed ID: 24549965
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dermal flurbiprofen nanosuspensions: Optimization with design of experiment approach and in vitro evaluation.
    Oktay AN; Karakucuk A; Ilbasmis-Tamer S; Celebi N
    Eur J Pharm Sci; 2018 Sep; 122():254-263. PubMed ID: 29981401
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recent Advances in Nanosuspension Technology for Drug Delivery.
    Arora D; Khurana B; Rath G; Nanda S; Goyal AK
    Curr Pharm Des; 2018; 24(21):2403-2415. PubMed ID: 29788880
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exploring the influence factors and improvement strategies of drug polymorphic transformation combined kinetic and thermodynamic perspectives during the formation of nanosuspensions.
    Meng T; Qiao F; Ma S; Gao T; Li L; Hou Y; Yang J
    Drug Dev Ind Pharm; 2021 Dec; 47(12):1867-1880. PubMed ID: 35362347
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preparation, characterization and pharmacokinetics of cyadox nanosuspension.
    Sattar A; Chen D; Jiang L; Pan Y; Tao Y; Huang L; Liu Z; Xie S; Yuan Z
    Sci Rep; 2017 May; 7(1):2289. PubMed ID: 28536446
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biocompatible riboflavin laurate long-acting injectable nanosuspensions allowing sterile filtration.
    Hu X; Lin X; Gu Y; Liu Z; Tang Y; Zhang Y; Chen X; Wang Y; Tang X
    Drug Deliv; 2014 Aug; 21(5):351-61. PubMed ID: 24188474
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nanosuspensions Containing Oridonin/HP-β-Cyclodextrin Inclusion Complexes for Oral Bioavailability Enhancement via Improved Dissolution and Permeability.
    Zhang X; Zhang T; Lan Y; Wu B; Shi Z
    AAPS PharmSciTech; 2016 Apr; 17(2):400-8. PubMed ID: 26187778
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug nanosuspensions: a ZIP tool between traditional and innovative pharmaceutical formulations.
    Leone F; Cavalli R
    Expert Opin Drug Deliv; 2015; 12(10):1607-25. PubMed ID: 25960000
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of stabilizing agents on the development of myricetin nanosuspension and its characterization: an in vitro and in vivo evaluation.
    Hong C; Dang Y; Lin G; Yao Y; Li G; Ji G; Shen H; Xie Y
    Int J Pharm; 2014 Dec; 477(1-2):251-60. PubMed ID: 25445518
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development and evaluation of intramuscularly administered nano/microcrystal suspension.
    Ma Z; Zhang H; Wang Y; Tang X
    Expert Opin Drug Deliv; 2019 Apr; 16(4):347-361. PubMed ID: 30827123
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of drug physicochemical properties on absorption of water insoluble drug nanosuspensions.
    Li W; Quan P; Zhang Y; Cheng J; Liu J; Cun D; Xiang R; Fang L
    Int J Pharm; 2014 Jan; 460(1-2):13-23. PubMed ID: 24184036
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of a novel ophthalmic ciclosporin A-loaded nanosuspension using top-down media milling methods.
    Kim JH; Jang SW; Han SD; Hwang HD; Choi HG
    Pharmazie; 2011 Jul; 66(7):491-5. PubMed ID: 21812323
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nanosuspensions as delivery system for gambogenic acid: characterization and in vitro/in vivo evaluation.
    Yuan H; Li X; Zhang C; Pan W; Liang Y; Chen Y; Chen W; Liu L; Wang X
    Drug Deliv; 2016 Oct; 23(8):2772-2779. PubMed ID: 26292058
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preparation, Characterization and In Vivo Assessment of Repaglinide Nanosuspension for Oral Bioavailability Improvement.
    Zawar LR; Bari SB
    Recent Pat Drug Deliv Formul; 2018; 12(3):162-169. PubMed ID: 30003863
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nanosuspensions of poorly soluble drugs: preparation and development by wet milling.
    Liu P; Rong X; Laru J; van Veen B; Kiesvaara J; Hirvonen J; Laaksonen T; Peltonen L
    Int J Pharm; 2011 Jun; 411(1-2):215-22. PubMed ID: 21458552
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stability of nanosuspensions in drug delivery.
    Wang Y; Zheng Y; Zhang L; Wang Q; Zhang D
    J Control Release; 2013 Dec; 172(3):1126-41. PubMed ID: 23954372
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.